Vaccine

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Teva hosting investor call today at 8:00 a.m. ET (U.S.)Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD),…

1 week ago

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis…

1 week ago

Edison Issues Report on Mendus (IMMU)

London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway…

1 week ago

Medical Writing Market Size Indicating $ 9.09 billion by 2031, Featuring Profiles of Cactus Communications, Certara, Covance, Freyr Solutions, InClin Inc

The report from The Insight Partners lists several stakeholders—including pharmaceutical and biotech companies, CROs, regulatory authorities, healthcare providers, and academic…

2 weeks ago

IAVI and IPD Sign Agreement Formalizing Collaboration to Advance Vaccine Development, Manufacturing, and Access in Africa

Agreement signed to establish collaboration between IAVI and IPDNew partnership aims to accelerate vaccine development and manufacturing for priority pathogens…

2 weeks ago

Evaxion establishes new AI-derived precision cancer vaccine concept

Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical…

2 weeks ago

AARP Showcases Pioneering AgeTech Innovations at CES 2025

 New AARP CEO Dr. Myechia Minter-Jordan to Discuss Innovations Shaping the Future of Aging and Well-Being WASHINGTON, Dec. 11, 2024…

2 weeks ago

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6…

2 weeks ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…

2 weeks ago

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…

2 weeks ago